Cleared Special

K221160 - Xpert Xpress MVP, GeneXpert Dx System, GeneXpert Infinity System (FDA 510(k) Clearance)

Jun 2022
Decision
47d
Days
Class 2
Risk

K221160 is an FDA 510(k) clearance for the Xpert Xpress MVP, GeneXpert Dx System, GeneXpert Infinity System. This device is classified as a Vaginitis And Bacterial Vaginosis Nucleic Acid Detection System (Class II - Special Controls, product code PQA).

Submitted by Cepheid (Sunnyvale, US). The FDA issued a Cleared decision on June 7, 2022, 47 days after receiving the submission on April 21, 2022.

This device falls under the Microbiology FDA review panel. Regulated under 21 CFR 866.3975. A Vaginitis And Bacterial Vaginosis Nucleic Acid Detection System Is A Qualitative In Vitro Diagnostic Device For The Direct Detection Of Nucleic Acid Sequences From Microorganisms Associated With Vaginitis Or Bacterial Vaginosis. The Device Is Indicated For Individuals With Signs And Symptoms Of Vaginitis Or Bacterial Vaginosis And Aids In The Diagnosis Of These Vaginal Infections..

Submission Details

510(k) Number K221160 FDA.gov
FDA Decision Cleared Substantially Equivalent - Traditional 510(k) (SESE)
Date Received April 21, 2022
Decision Date June 07, 2022
Days to Decision 47 days
Submission Type Special
Review Panel Microbiology (MI)
Summary Summary PDF

Device Classification

Product Code PQA — Vaginitis And Bacterial Vaginosis Nucleic Acid Detection System
Device Class Class II - Special Controls
CFR Regulation 21 CFR 866.3975
Definition A Vaginitis And Bacterial Vaginosis Nucleic Acid Detection System Is A Qualitative In Vitro Diagnostic Device For The Direct Detection Of Nucleic Acid Sequences From Microorganisms Associated With Vaginitis Or Bacterial Vaginosis. The Device Is Indicated For Individuals With Signs And Symptoms Of Vaginitis Or Bacterial Vaginosis And Aids In The Diagnosis Of These Vaginal Infections.